Sylvie Gregoire - 17 Nov 2025 Form 4 Insider Report for CervoMed Inc. (CRVO)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: CRVO
Reported as of: 17 Nov 2025
Net transaction value: +$182,736
SEC form: 4
Accepted by SEC: 19 Nov 2025, 07:45:56 UTC
Prior SEC filing: 17 Nov 2025
Next SEC filing: 13 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ William R. Elder, attorney-in-fact for the Reporting Person

Key filing fact

Sylvie Gregoire filed Form 4 for CervoMed Inc. (CRVO) on 19 Nov 2025.

Key facts

This page summarizes Sylvie Gregoire's Form 4 filing for CervoMed Inc. (CRVO).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 19 Nov 2025, 07:45.

Change

Previous filing in this sequence was filed on 17 Nov 2025.
Current net transaction value: +$182,736.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001335822 Primary reporting owner

Gregoire Sylvie

Relationship: Director, 10%+ Owner
Address: 20 PARK PLAZA, SUITE 424, BOSTON
Signature: /s/ William R. Elder, attorney-in-fact for the Reporting Person
Signature date: 19 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRVO transaction

Common Stock

Purchase

Transaction value: $91,309
Shares: +10,793
Change %: +0.73%
Price: $8.46
Shares after: 1,484,078
Date: 17 Nov 2025
Ownership: Direct
Footnotes: F1, F2, F3

CRVO transaction

Common Stock

Purchase

Transaction value: $91,427
Shares: +10,807
Change %: +638%
Price: $8.46
Shares after: 12,500
Date: 17 Nov 2025
Ownership: Spouse's IRA
Footnotes: F1, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Shares purchased in open-market transactions.

Footnote F2

The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $8.38 to $8.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range.

Footnote F3

Includes (i) 1,471,578 hares held jointly by the Reporting Person and her spouse, Dr. John Alam, M.D., the Issuer's President & Chief Executive Officer and a member of the Issuer's Board of Directors and (ii) 12,500 shares held by the Sylvie Gregoire Roth IRA.

Footnote F4

Shares held by the John J. Alam Roth IRA.

Footnote F5

The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $8.39 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range.